Diabetes

GLP-1RAs produce greater weight loss results among women than men, a 2026 systematic review and meta-analysis has found.

The FDA has issued warning letters to 30 telehealth companies for reportedly making false claims about GLP-1 products, amid a major crackdown on pharmaceutical advertisements.

Nicotine-seeking behaviours and activity in the brain’s reward pathway have been found to be dampened through the activation of glucose-like peptide-1 receptors.

A new non-peptide GLP-1 pill proved more effective for weight loss than oral semaglutide in a recent Phase III trial.

At 48 weeks, 58% of participants in the treatment group lost more than 5% of their total body weight, meeting the responder rate co-primary endpoint.

Altitude reduces the risk of diabetes due to red blood cells acting as the primary glucose sink during hypoxia, a 2026 study has found.

Metabolic and bariatric surgery offers greater cardiovascular protection than GLP-1 receptor agonists, a 2026 systematic review and meta-analysis has found.

Prescribing patients with type 2 diabetes SGLT-2 inhibitors much earlier in the treatment process could prevent around 17,000 deaths in the UK, new NICE guidance suggests.